DLL3-Targeted PET/CT in Small Cell Lung Cancer

Summary

The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed small cell lung cancer, and to compare with conventional imaging modalities.

Eligibility

Inclusion Criteria:

* Adult patients (aged 18 years or older);
* Patients with suspected, newly diagnosed, and previously treated small cell lung cancer(supporting evidence may include imaging findings and pathology report);
* Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;
* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;

Exclusion Criteria:

* The inability or unwillingness of the research participant or legal representative to provide written informed consent.
* Inability to complete PET/CT imaging.

Conditions6

Browse More Trials